Novo Nordisk and AI-driven Gensaic enter into $354m cardiometabolic deal
Novo Nordisk has signed a deal with AI-driven protein design company Gensaic to develop tissue-targeted therapies for ...
BioSpace4h
Obesity Late-Comer AbbVie Inks Up to $2.2B Amylin Deal With Gubra
AbbVie on Monday jumped into the hot weight-loss space, looking to gain ground on its Big Pharma peers, with a licensing deal ...
Jim Cramer on Novo Nordisk A/S (NVO): ‘Where Are They Going To Be In The Tariffs’
We recently published an article titled Jim Cramer Discusses These 12 Stocks & Says Late Selloffs Are Deliberate. In this ...
California made a big bet on producing its own insulin. There’s no ‘date certain’ for delivery
California dedicated $100 to manufacturing insulin for diabetic residents. That effort is taking longer than Gov. Gavin Newsom's initial timeline.
Gensaic Announces Collaboration with Novo Nordisk to Unlock Next Generation Precision Therapies
Gensaic partnership with Novo Nordisk, worth up to $354M, aims to develop next-generation precision therapies using novel protein design technology.
AbbVie, Gubra in Obesity-Drug License Pact Potentially Worth More Than $2 Billion
AbbVie is jumping into the burgeoning obesity field, striking a license agreement with Gubra that is potentially worth more than $2 billion to the Danish drug-discovery and contract-research-services ...
India's Sun Pharma aims to launch its obesity drug in five years, managing director says
India's largest drugmaker by revenue Sun Pharmaceutical is aiming to launch its experimental anti-obesity and type 2 diabetes ...
These discounted versions of popular weight-loss drugs are going away: What to know
Consumers who use telehealth or medical spas to get less expensive, compounded weight loss drugs will need to get their ...
MM&M2d
Faced with compounded drugs, Eli Lilly tells consumers to ‘be a healthy skeptic’
Eli Lilly is seeking to further cement its stance as a leader in weight loss drugs in an ad campaign calling out “unapproved” medications.
Modern Healthcare4d
GLP-1 compounding pharmacies sue FDA over shortage decision
Outsourcing Facilities Association and North American Custom Laboratories allege the FDA removed semaglutide from its ...
The American Journal of Managed Care4d
Medicare Part D Spending Trends for Type 2 Diabetes Medications
New diabetes medications are pressuring Medicare Part D financially as they drive up prescription drug costs amid rising ...
Prediction: Novo Nordisk Will Soar Over the Next 5 Years. Here's 1 Reason Why.
Novo Nordisk and Eli Lilly (with its Zepbound) are the two reigning kings on the U.S. market these days. There will be more contenders; Viking Therapeutics, in particular, is in the later stages of ...